Ensysce Biosciences vs Kyntra Bio
ENSC and KYNB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENSC and KYNB compare
Kyntra Bio is the larger company, worth 1.6 times as much as Ensysce Biosciences ($13.0M against $8.0M).
Kyntra Bio grew revenue faster over the last twelve months (−37.1% versus −39.3% for Ensysce Biosciences).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENSC | KYNB |
|---|---|---|
| Size and price | ||
| Market cap | $8.0M | $13.0M |
| Share price | $0.409 | $3.20 |
| Change, 1 year | −80.2% | −64.7% |
| Change, 5 years | −100.0% | −98.9% |
| Beta (5Y) | 3.68 | 1.52 |
| Employees | 8 | 34 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 0.1× |
| P/S | 1.8× (better) | 2.8× |
| FCF yield | – | −294% |
| Growth | ||
| Revenue growth (TTM) | −39.3% | −37.1% (better) |
| Revenue growth, 5Y average | 5.2% (better) | −48.4% |
| Profitability | ||
| Gross margin | – | 6.3% |
| Operating margin | −281% (better) | −1090% |
| Net margin | – | 3968% |
| FCF margin | – | −824% |
| Financial health | ||
| Interest coverage | −791.6× | −5.4× (better) |
| Current ratio | 0.70 | 2.69 (better) |
| Altman Z-score | −80.97 | −24.48 (better) |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.7% | 24.7% |
| Held by insiders | 6.2% | 15.7% |
| Insider net buying, 12 months | $444K (better) | $39.7K |
| Short interest, % of float | 0.49% | 2.8% |
Go deeper
- ENSC stock overview
- ENSC income statement
- ENSC valuation and score
- KYNB stock overview
- KYNB income statement
- KYNB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.